Results of an Open-label, Phase 1a/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced or Metastatic Soft Tissue Sarcoma.

Patrick Schöffski,Rastislav Bahleda,Andrew J Wagner,Melissa A Burgess,Niels Junker,Michael Chisamore,Patrick Peterson,Anna M Szpurka,Matteo Ceccarelli,William D Tap

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览1

暂无评分

摘要

Antitumor activity was observed in some patients in DEC, combination was well tolerated with manageable safety profile. Further studies are warranted to evaluate efficacy/mechanistic impact of platelet-derived growth factor receptors inhibitor with immune checkpoint modulator coadministration.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要